Summary
CarrerasLeaders is the postdoctoral program hosted by the Josep Carreras Leukaemia Research Institute (IJC) and co-funded by the Marie Skłodowska-Curie (MSCA) Actions.
The program will fund 16 excellent postdoctoral researchers for a period of 3 years. Applicants have complete freedom of research choice within the scope of blood cancers. CarrerasLeaders fellows will benefit from highly attractive working conditions in the healthy, inspiring, and creative working environment of the IJC, receive tailored training and mentoring.
Suitable applicants have less than 7 years of postdoc experience, demonstrated their capacity to perform high-quality research and are interested to move to Spain. They have free choose of any of the IJC’s group and platform leaders as future supervisor. They will propose collaborative projects involving international and intersectoral partners through secondments. The selection is merit-based, founded on peer review in an open and transparent selection procedure. Detailed eligibility criteria, info on the selection process and a list of all participating labs can be found in the ‘Apply’ section (INSERT link).
The CarrerasLeaders program has the following larger objectives:
- To empower the next generation of scientific leaders to advance on the cure of blood cancers.
- To boost career perspective of researchers from the three-dimensional perspective of consolidation, leadership and independence.
- To improve the quality of postdoctoral training by addressing the societal needs in blood cancer and tailoring it to individual researchers.
- To enhance cooperation and transfer knowledge between sectors and disciplines.
- To increase the competitiveness of the IJC in the world-wide research and innovation community.
Through training of experts, collaborative research and the fast-horizontal transfer of knowledge the research program of CarrerasLeaders holds the promise to advance on the many remaining unmet medical needs in haematological cancers and to participate in the delivery of new solutions to the Cancer Mission of Horizon Europe.
Institutions
| Partner organisation name | Country | Academic | Secondment |
| Fundació Internacional Josep Carreras | ES | ||
| International Society for Experimental Hematology | US | ||
| Asociación Española Contra el Cáncer | ES | ||
| Fundació Institució dels Centres de Recerca de Catalunya | ES | ||
| Agència de Gestió d’Ajuts Universitaris i de Recerca | ES | ||
| Leadership Sculptor GmbH | GE | ||
| Fundación Científica de la Asociación Española Contra el Cáncer | ES | ||
| ThePaperMill | ES | ||
| European Hermatology Association | NL | ||
| Scienseed SL | ES |  |
|
| IBM Research GmbH | CH | |
|
| IMMAGINA BioTechnology SRL | IT | |
|
| Milteny Biotech BV & CO KG | DE | |
|
| Quimatryx SL | ES | |
|
| MLL Munchner Leukamielabor GmbH | DE | |
|
| Applied Nanoparticles SL | ES | |
|
| Applied Research using Omic Sciences SL | ES | |
|
| OneChain Immunotherapeutics | ES | |
|
| GenomeScan B.V. | NL | |
|
| Zeclinics SL | ES | |
|
| Anaxomics Biotech SL | ES | |
|
| Humanitas Mirasole SPA | IT | |
|
| Université Libre de Bruxelles | BE | |
|
| Max Planck Gesellschaft zur Forderung der Wissencschaften EV | DE | |
|
| University of Newcastle upon Tyne | UK | |
|
| Genome Research limited (Wellcome Sanger Institute) | UK | |
|
| CharitéCentrum für Tumormedizin | DE | |
|
| Instituto de Medicina Molecular João Lobo Antunes | PT | |
|
| Fondazione per l’Istituto Oncologico di Ricerca (IOR) | CH | |
|
| Trustees of Columbia University in the city of New York | US | |
|
| New York University | US | |
|
| Agencia Estatal Consejo Superior de Investigaciones Científicas | ES | |
|
| Ústav molekulární genetiky akademie ved ceske republiky verejna vyzkumna instituce | CZ | |
|
| Medizinische Hochschule Hannover | DE | |
|
| Deutsches Krebsforshungszentrum Heidelberg | DE | |
|
| Universitetet i Oslo | NO | |
|
| Fundació Institut de Recerca Biomèdica | ES | |
|
| Kither Biotech SRL | IT | |
|
| Novogene (UK) Company Limited | UK | |
|
| Ecole Polytechnique Fédérale de Lausanne | CH | |
|
| MESOESTETIC Pharma Group SL | ES | |
|
| Semmelweis University | H | |
|
Expected results
On the institutional level
- Recruiting international top talent researchers, strengthening IJC research and innovation capacity and output. Additionally, enhancing the international visibility and attractiveness of IJC and positively impacting on the institute’s future capacity to attract international talent and funding.
- Enhancing the quality, sustainability and diversity of the research and transferable skills training.
- Consolidating and establishing new collaborations between the IJC with its ecosystem while enhancing the institute’s network and training opportunities for research staff at new Associated Partners acting as secondment hosts.
- Support and train Associated Partners in Widening Countries to improve the research and clinical treatments on blood diseases.
On the regional and national level
- Enriching the BioRegion of Barcelona and Catalonia, a leading life sciences and health hub in Europe.
- Boosting regional competitiveness and creating value in the regional health sector by promoting research and innovation.
- Dissemination of the program and its outcomes to its R&I ecosystem, health and medical authorities and policy makers.
On European and international level
- Contributing to strengthening the skills development and mobility of researchers across borders.
- CarrerasLeaders will strengthen the research and innovation capacity of the IJC and its Associated Partners and increase their scientific production.
- CarrerasLeaders will also foster the European competitiveness in terms of greater transnational cohesion of HR and value chain efforts on common Cancer research topics.
